It was found that the SLC16A3 gene alteration rate is highest (> 4%) in hepatobiliary cancer, endometrial cancer, pleural mesothelioma, breast cancer, and ovarian epithelial tumor (Fig. 8A), Amplification, miss mutation, and deep deletion are the main. This evidence concerns the gene SLC16A3 and endometrial cancer.